News

Relievant Medsystems Announces $70M Financing to Accelerate U.S. Commercialization of Intracept Procedure

Relievant Medsystems Announces $70M Financing to Accelerate U.S. Commercialization of Intracept Procedure OCTOBER 29, 2020 – MINNEAPOLIS, MN. Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), announced today the completion of a $70 million equity financing. The round was led [...]

2026-11-11T13:04:49+00:00October 29th, 2020|All News, Blog|

Lumeon Raises $30M in Funding to Support U.S. Growth

Lumeon Raises $30M in Funding to Support U.S. Growth New investment will expand care delivery platform solutions and enable deeper healthcare provider partnerships  BOSTON – Aug 11, 2020 – Lumeon, the leader in care pathway orchestration, today announced that it has closed $30M in Series D funding led [...]

2023-03-30T15:41:20+01:00August 11th, 2020|All News, Blog|

Polares Medical Closes a $40M Financing to Complete Pilot Clinical Studies

Polares Medical Closes a $40M Financing to Complete Pilot Clinical Studies Lausanne & Palo Alto, June 25, 2020. Polares Medical SA, a clinical-stage medical technology company focused on the development of a unique trans-catheter mitral valve hemi-replacement system to treat patients suffering from mitral regurgitation (MR), announced today [...]

2023-04-03T13:27:32+01:00June 26th, 2020|All News, Blog|

Relievant announces publication of 5-Year data demonstrating long-term clinical benefits of the Intracept procedure in chronic low back pain patients

MINNEAPOLIS, June 08, 2020 (GLOBE NEWSWIRE) -- Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced European Spine Journal publication of long-term data from the Level I SMART trial showing durability of improvements in pain and function beyond 5 years [...]

2023-04-12T13:30:05+01:00June 8th, 2020|All News, Company News|

Rapid Micro Biosystems Raises $120 Million to Accelerate Global Expansion of Contaminant Testing Platform for Pharmaceutical and Vaccine Manufacturing

Proceeds will enable the company to meet growing demand for its automated microbial detection platform, currently used by a majority of the top 20 global biopharmaceutical companies, and support new product development for pandemic response. Global investor syndicate is led by Ally Bridge Group, joined by Endeavour Vision, and [...]

2023-04-03T15:13:17+01:00May 20th, 2020|All News, Blog|

Endeavour Vision leads investment in Intelycare’s artificial intelligence-driven nurse staffing platform, to support the next phase of the company’s growth

Geneva, February 20, 2020 - Endeavour Vision led the Series B funding round for Boston-based IntelyCare, along with Kaiser Permanente Ventures and Generator Ventures, allowing the company to raise $45 million in new equity and debt financing. With aging populations and an increase in chronic diseases, more people need [...]

2023-04-03T15:41:08+01:00February 20th, 2020|All News, Company News, Investment|

V-Wave’s Interatrial Shunt Receives FDA Breakthrough Device Designation for Heart Failure

V-Wave’s Interatrial Shunt Receives FDA Breakthrough Device Designation for Heart Failure CAESAREA, Israel, Aug. 15, 2019 — V-Wave Ltd., a privately held medical device company developing novel implantable interatrial shunt devices, today announced that the U.S. Food and Drug Administration (FDA) has just granted the company a Breakthrough [...]

2023-04-03T11:08:50+01:00August 19th, 2019|All News, Company News|

CeQur appoints Bradley Paddock Chief Executive Officer

Medical Device Veteran Has 23-Year Record of Successful Commercial and Organizational Leadership MARLBOROUGH, Mass., June 5, 2019 — CeQur® announced that the company has appointed Bradley Paddock as chief executive officer, effective today. Paddock brings a track record of commercial medtech successes, notably leading sales up to $600 million [...]

2023-04-12T12:40:58+01:00June 6th, 2019|All News, Blog, Company News|
Go to Top